Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker

Clinical Therapeutics

Volumn 20, Issue 6, 1998, Pages 1106-1114

  Pool, James ^a,e   Oparil, Suzanne ^b   Hedner, Thomas ^c   Glazer, Robert ^d   Oddou Stock, Pascale ^d   Hester, Allen ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin II receptor blocker; Dose response; Hypertension; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; PLACEBO; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

EID: 0032418657     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80107-0     Document Type: Conference Paper

References (30)

1. 1. Oparil S. Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in. Curr Opin Nephrol Hypertens. 1996;5:159-161.
2. 2. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens. 1996;18:463-472.
3. 3. Johnston GD. Dose-response relationships with antihypertensive drugs. Pharmacol Ther. 1992;55:53-93.
4. 4. Foote EF, Halstenson CE. New therapeutic agents in the management of hypertension: Angiotensin II - receptor antagonists and renin inhibitors. Ann Pharmacother. 1993;27:1495-1503.
5. 5. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54:299-311.
6. 6. Man in't Veld AJ. Clinical overview of irbesartan: Expanding the therapeutic window in hypertension. J Hypertens Suppl. 1997;15:S27-S33.
7. 7. Simon TA, Gelarden RT, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol. 1998;82:179-182.
8. 8. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998;7:53-59.
9. 9. Weber M. Clinical safety and tolerability of losartan. Clin Ther. 1997;19:604-616.
10. 10. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995:25:1345-1350.
11. 11. Reeves RA, Lin C-S, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension. 1998;31:1311-1316.
12. 12. Pool JL, Guthrie RM, Littlejohn TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998;11:462-470.
13. 13. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens. 1997;11(Suppl 2):S49-S53.
14. 14. de Gasparo M, Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. 1995;59:303-311.
15. 15. Criscione L, Bradley A, Bühlmayer P, et al. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev. 1995;13:230-250.
16. 16. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
17. 17. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997;52:173-177.
18. 18. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14:1147-1151.
19. 19. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11:483-489.
20. 20. Oddou-Stock P, Gatlin M, Kobi P, et al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension. Am J Hypertens. 1997;10:84A. Abstract.
21. 21. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797-810.
22. 22. Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: Results from one and two year trials. J Clin Res. 1998;1:147-159.
23. 23. Black H, Reed J, Fitzsimmons S, Shi Y. The combination of valsartan and hydrochlorothiazide is effective and well tolerated in essential hypertension. Am J Hypertens. 1998;11:D006. Abstract.
24. 24. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. Summary of 1993 World Health Organisation - International Society of Hypertension guidelines for the management of mild hypertension. BMJ. 1993;307:1541-1546.
25. 25. MacMahon S, Rodgers A, Neal B, Chalmers J. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension. 1997;29:537-538.
26. 26. Mallion J-M, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist: Efficacy and tolerability compared with an angiotensin converting enzyme inhibitor enalapril in essential hypertension. Blood Press Monit. 1997;2:179-185.
27. 27. Peto R, Collins R, Gray R. Large-scale randomized evidence: Large, simple trials and overviews of trials. J Clin Epidemiol. 1995;48:23-40.
28. 28. Swales JD. Meta-analysis as a guide to clinical practice. J Hypertens Suppl. 1993;11:S59-S63.
29. 29. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. In press.
30. 30. Dallas Hall W, Montoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest. 1998;16:203-210.